OVID Ovid Therapeutics Inc. Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
23:38
Aug 19
seedy19tron Biotech trader, L/S
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
OVID
23:36
Aug 19
seedy19tron Biotech trader, L/S
Top biotech picks across various therapeutic areas
Author lists these biotech names as their best ideas across various therapeutic areas with the sector near all-time highs.
OVID
MED
05:59
Jul 27
seedy19tron Biotech trader, L/S
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE.
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE acquisition, celebrating broad sector gains without explicit forward calls on most names.
OVID
LOW
13:13
Jun 21
seedy19tron Biotech trader, L/S
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
OVID
MED
00:55
Jun 21
seedy19tron Biotech trader, L/S
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
OVID
LOW
13:25
Mar 18
seedy19tron Biotech trader, L/S
The author expresses a positive outlook on OVID data and expects the stock price to exceed $3.
18:29
Mar 15
seedy19tron Biotech trader, L/S
The author provides a routine portfolio update detailing additions, reductions.
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
OVID

About OVID Analyst Coverage

Buzzberg tracks OVID (Ovid Therapeutics Inc.) across 1 sources. 2 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (29%). 7 total trade ideas tracked. Latest voices: seedy19tron.